Abstracts tagged "Rheumatoid arthritis (RA) and teriparatide"

Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 2260 • 2014 ACR/ARHP Annual Meeting
Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients
Kumiko Ono¹, Satoru Ohashi², Hiroyuki Oka³, Yuho Kadono⁴, Tetsuro Yasui⁴, Yasunori Omata⁴, Naoko Shoda⁴ and Sakae Tanaka¹, ¹Orthopaedic Surgery and Spinal Surgery, The University of Tokyo Hospital, Tokyo, Japan, ²Department of Orthopaedic Surgery, Sagamihara Hospital,National Hospital Organization, Kanagawa, Japan, ³Department of Joint Disease Research, 22nd Century Medical & Research Center, faculty of medicine,the university of Tokyo, Tokyo, Japan, ⁴Department of Orthopaedic Surgery and Spine Surgery, The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) decreases bone mineral density and bone quality, and exposes patients to an increased risk of fracture. In RA treatment, improvement of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].